...Thank you, Towanda and those of you attending today's quarterly review. Dr. Shai Gozani, President and CEO of NeuroMetrix, is participating in this call. For those unfamiliar, we are a Boston-based medical device company focused on reducing the impact of neurological disorders and pain syndromes, both on individuals and on populations. Our technologies are noninvasive. We hold extensive proprietary intellectual property. Our business model is based on recurring revenue from a customer installed base. And our principal products are DPNCheck, a diagnostic device providing rapid point-of-care detection of peripheral neuropathy; and Quell, a wearable neurostimulation device indicated for symptomatic relief of lower extremity chronic pain. Revenues in the fourth quarter of the year were $1.8 million. This is flat with Q4 of last year. Full year revenues of $8.3 million were up 11.9% from the prior year. DPNCheck sales to U.S. Medicare Advantage accounts constitute the majority of revenue. Medicare...
